Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma
| Autor: | John D. Heiss, Sriya Namagiri, Guruprasad Rachaiah, Toshihiko Shimizu, Yuanqing Yan, Hannah Sur, Prashant Chittiboina, Leomar Y. Ballester, Balveen Kaur, Amelie Vezina, Zhuang Zhengping, Cole T. Lewis, Ashis Chowdhury, Xiang Wang, Ji Young Yoo, Dragan Maric, Yoshihiro Otani, Sadhana Jackson, Yeshavanth Kumar Banasavadi-Siddegowda, Arunakumar Gangaplara, Sachin Kumar, Abhik Ray-Chaudhury |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Protein-Arginine N-Methyltransferases
Cancer Research Combination therapy Arginine medicine.diagnostic_test Chemistry Necroptosis Protein arginine methyltransferase 5 Phosphatase Editorials Protein phosphatase 2 Xenograft Model Antitumor Assays Piperazines Mice Oncology Western blot In vivo Cell Line Tumor medicine Cancer research Animals Humans Protein Phosphatase 2 Neurology (clinical) Glioblastoma |
| Zdroj: | Neuro Oncol |
| ISSN: | 1523-5866 1522-8517 |
| Popis: | Background Despite multi-model therapy of maximal surgical resection, radiation, chemotherapy, and tumor-treating fields, the median survival of glioblastoma (GBM) patients is less than 15 months. Protein arginine methyltransferase 5 (PRMT5) catalyzes the symmetric dimethylation of arginine residues and is overexpressed in GBM. Inhibition of PRMT5 causes senescence in stem-like GBM tumor cells. LB100, a first-in-class small molecular inhibitor of protein phosphatase 2A (PP2A), can sensitize therapy-resistant tumor cells. Here, we tested the anti-GBM effect of concurrent PRMT5 and PP2A inhibition. Methods Patient-derived primary GBM neurospheres (GBMNS), transfected with PRMT5 target-specific siRNA, were treated with LB100 and subjected to in vitro assays including PP2A activity and western blot. The intracranial mouse xenograft model was used to test the in vivo antitumor efficacy of combination treatment. Results We found that PRMT5 depletion increased PP2A activity in GBMNS. LB100 treatment significantly reduced the viability of PRMT5-depleted GBMNS compared to PRMT5-intact GBMNS. LB100 enhanced G1 cell cycle arrest induced by PRMT5 depletion. Combination therapy also increased the expression of phospho-MLKL. Necrostatin-1 rescued PRMT5-depleted cells from the cytotoxic effects of LB100, indicating that necroptosis caused the enhanced cytotoxicity of combination therapy. In the in vivo mouse tumor xenograft model, LB100 treatment combined with transient depletion of PRMT5 significantly decreased tumor size and prolonged survival, while LB100 treatment alone had no survival benefit. Conclusion Overall, combined PRMT5 and PP2A inhibition had significantly greater antitumor effects than PRMT5 inhibition alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|